Dr. Kennedy is the founding chair of the Canadian Network for Mood and Anxiety Treatment (CANMAT), which has produced treatment guidelines for depression and for bipolar disorder since 1995 to advance treatment for individuals, guide practitioners and influence health systems. He is the principal investigator of the Canadian Biomarker Integration Network in Depression (CAN-BIND), a national consortium of research and learning that is dedicated to defining distinct profiles associated with subgroups of people with depression, ultimately matching them to the right treatment. This consortium is sponsored by the Ontario Brain Institute. Dr. Kennedy is also the lead psychiatrist on the application of deep brain stimulation to treatment-resistant depression and conducts studies to evaluate neuroimaging changes with treatment.
Senior Scientist, Krembil Research Institute (Krembil)
Professor, Department of Psychiatry, University of Toronto
Professor, Institute of Medical Science, University of Toronto
Principal Investigator, Canadian Biomarker Integration Network for Depression (CAN-BIND)